These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 18473713)
1. Telmisartan as a metabolic sartan for targeting vascular failure. Inoue T; Node K Expert Opin Pharmacother; 2008 Jun; 9(8):1397-406. PubMed ID: 18473713 [TBL] [Abstract][Full Text] [Related]
2. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Yamagishi S; Takeuchi M Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852 [TBL] [Abstract][Full Text] [Related]
3. Telmisartan: a different angiotensin II receptor blocker protecting a different population? Burnier M J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. Tuck ML Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040 [TBL] [Abstract][Full Text] [Related]
5. Telmisartan, its potential therapeutic implications in cardiometabolic disorders. Yamagishi S; Nakamura K Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):79-83. PubMed ID: 18221077 [TBL] [Abstract][Full Text] [Related]
6. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. Ono Y; Nakaya Y; Bando S; Soeki T; Ito S; Sata M Int Heart J; 2009 Jan; 50(1):73-83. PubMed ID: 19246848 [TBL] [Abstract][Full Text] [Related]
7. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185 [TBL] [Abstract][Full Text] [Related]
8. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643 [TBL] [Abstract][Full Text] [Related]
10. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Yamagishi S; Nakamura K; Matsui T Curr Mol Med; 2007 Aug; 7(5):463-9. PubMed ID: 17691961 [TBL] [Abstract][Full Text] [Related]
11. Are the pleiotropic effects of telmisartan clinically relevant? Rizos CV; Elisaf MS; Liberopoulos EN Curr Pharm Des; 2009; 15(24):2815-32. PubMed ID: 19689352 [TBL] [Abstract][Full Text] [Related]
12. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150 [TBL] [Abstract][Full Text] [Related]
13. Telmisartan: just an antihypertensive agent? A literature review. Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832 [TBL] [Abstract][Full Text] [Related]
14. Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice? Fujimura A; Ushijima K; Ando H Hypertens Res; 2013 Feb; 36(2):183. PubMed ID: 23190691 [No Abstract] [Full Text] [Related]
15. Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan. Inoue T; Taguchi I; Abe S; Toyoda S; Sakuma M; Node K J Clin Pharm Ther; 2011 Feb; 36(1):103-10. PubMed ID: 21198725 [TBL] [Abstract][Full Text] [Related]